High-dose cyclophosphamide in severe aplastic anaemia

A randomised trial

John F. Tisdale, Daniel E. Dunn, Nancy Geller, Michelle Plante, Olga Nunez, Cynthia E. Dunbar, A. John Barrett, Thomas J. Walsh, Stephen J. Rosenfeld, Neal S. Young

Research output: Contribution to journalArticle

Abstract

Background: High-dose cyclophosphamide has been proposed as an alternative immunosuppressive agent for treatment of severe aplastic anaemia, with a response rate similar to that with regimens containing antithymocyte globulin (ATG) but neither relapse nor clonal haematological complications. We undertook a phase III, prospective, randomised trial to compare response rates to immunosuppression with either high-dose cyclophosphamide plus ciclosporin or conventional immunosuppression with ATG plus ciclosporin in previously untreated patients. Methods: Between June, 1997, and March, 2000, 31 patients were enrolled. 15 were assigned cyclophosphamide (1 h intravenous infusion of 50 mg/kg daily for 4 days) and 16 were assigned ATG (40 mg/kg daily for 4 days); both groups received ciclosporin, initially at 12 mg/kg daily with adjustment to maintain concentrations at 200-400 μg/L, for 6 months. The primary endpoint was haematological response (no longer meeting criteria for severe aplastic anaemia). The trial was terminated prematurely after three early deaths in the cyclophosphamide group. Analyses were by intention to treat. Findings: Median follow-up was 21.9 months (range 1-33). There was excess morbidity in the cyclophosphamide group (invasive fungal infections, four cyclophosphamide vs no ATG patients; p=0.043) as well as excess early mortality (three deaths within the first 3 months cyclophosphamide vs no ATG patients; p=0.101). There was no significant difference at 6 months after treatment in the overall response rates among evaluable patients (six of 13 [46%] cyclophosphamide vs nine of 12 [75%] ATG). Interpretation: A longer period of observation will be necessary to assess the secondary endpoints of relapse and late clonal complications as well as disease-free and overall survival. However, cyclophosphamide seems a dangerous choice for treatment of this disorder, given the good results achievable with standard therapy.

Original languageEnglish (US)
Pages (from-to)1554-1559
Number of pages6
JournalThe Lancet
Volume356
Issue number9241
StatePublished - Nov 4 2000
Externally publishedYes

Fingerprint

Aplastic Anemia
Cyclophosphamide
Antilymphocyte Serum
Cyclosporine
Immunosuppression
Recurrence
Intention to Treat Analysis
Therapeutics
Immunosuppressive Agents
Intravenous Infusions
Disease-Free Survival
Observation
Morbidity
Mortality

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Tisdale, J. F., Dunn, D. E., Geller, N., Plante, M., Nunez, O., Dunbar, C. E., ... Young, N. S. (2000). High-dose cyclophosphamide in severe aplastic anaemia: A randomised trial. The Lancet, 356(9241), 1554-1559.

High-dose cyclophosphamide in severe aplastic anaemia : A randomised trial. / Tisdale, John F.; Dunn, Daniel E.; Geller, Nancy; Plante, Michelle; Nunez, Olga; Dunbar, Cynthia E.; Barrett, A. John; Walsh, Thomas J.; Rosenfeld, Stephen J.; Young, Neal S.

In: The Lancet, Vol. 356, No. 9241, 04.11.2000, p. 1554-1559.

Research output: Contribution to journalArticle

Tisdale, JF, Dunn, DE, Geller, N, Plante, M, Nunez, O, Dunbar, CE, Barrett, AJ, Walsh, TJ, Rosenfeld, SJ & Young, NS 2000, 'High-dose cyclophosphamide in severe aplastic anaemia: A randomised trial', The Lancet, vol. 356, no. 9241, pp. 1554-1559.
Tisdale JF, Dunn DE, Geller N, Plante M, Nunez O, Dunbar CE et al. High-dose cyclophosphamide in severe aplastic anaemia: A randomised trial. The Lancet. 2000 Nov 4;356(9241):1554-1559.
Tisdale, John F. ; Dunn, Daniel E. ; Geller, Nancy ; Plante, Michelle ; Nunez, Olga ; Dunbar, Cynthia E. ; Barrett, A. John ; Walsh, Thomas J. ; Rosenfeld, Stephen J. ; Young, Neal S. / High-dose cyclophosphamide in severe aplastic anaemia : A randomised trial. In: The Lancet. 2000 ; Vol. 356, No. 9241. pp. 1554-1559.
@article{1c5aa41738c946498ff63b54c9fdc707,
title = "High-dose cyclophosphamide in severe aplastic anaemia: A randomised trial",
abstract = "Background: High-dose cyclophosphamide has been proposed as an alternative immunosuppressive agent for treatment of severe aplastic anaemia, with a response rate similar to that with regimens containing antithymocyte globulin (ATG) but neither relapse nor clonal haematological complications. We undertook a phase III, prospective, randomised trial to compare response rates to immunosuppression with either high-dose cyclophosphamide plus ciclosporin or conventional immunosuppression with ATG plus ciclosporin in previously untreated patients. Methods: Between June, 1997, and March, 2000, 31 patients were enrolled. 15 were assigned cyclophosphamide (1 h intravenous infusion of 50 mg/kg daily for 4 days) and 16 were assigned ATG (40 mg/kg daily for 4 days); both groups received ciclosporin, initially at 12 mg/kg daily with adjustment to maintain concentrations at 200-400 μg/L, for 6 months. The primary endpoint was haematological response (no longer meeting criteria for severe aplastic anaemia). The trial was terminated prematurely after three early deaths in the cyclophosphamide group. Analyses were by intention to treat. Findings: Median follow-up was 21.9 months (range 1-33). There was excess morbidity in the cyclophosphamide group (invasive fungal infections, four cyclophosphamide vs no ATG patients; p=0.043) as well as excess early mortality (three deaths within the first 3 months cyclophosphamide vs no ATG patients; p=0.101). There was no significant difference at 6 months after treatment in the overall response rates among evaluable patients (six of 13 [46{\%}] cyclophosphamide vs nine of 12 [75{\%}] ATG). Interpretation: A longer period of observation will be necessary to assess the secondary endpoints of relapse and late clonal complications as well as disease-free and overall survival. However, cyclophosphamide seems a dangerous choice for treatment of this disorder, given the good results achievable with standard therapy.",
author = "Tisdale, {John F.} and Dunn, {Daniel E.} and Nancy Geller and Michelle Plante and Olga Nunez and Dunbar, {Cynthia E.} and Barrett, {A. John} and Walsh, {Thomas J.} and Rosenfeld, {Stephen J.} and Young, {Neal S.}",
year = "2000",
month = "11",
day = "4",
language = "English (US)",
volume = "356",
pages = "1554--1559",
journal = "The Lancet",
issn = "0140-6736",
publisher = "Elsevier Limited",
number = "9241",

}

TY - JOUR

T1 - High-dose cyclophosphamide in severe aplastic anaemia

T2 - A randomised trial

AU - Tisdale, John F.

AU - Dunn, Daniel E.

AU - Geller, Nancy

AU - Plante, Michelle

AU - Nunez, Olga

AU - Dunbar, Cynthia E.

AU - Barrett, A. John

AU - Walsh, Thomas J.

AU - Rosenfeld, Stephen J.

AU - Young, Neal S.

PY - 2000/11/4

Y1 - 2000/11/4

N2 - Background: High-dose cyclophosphamide has been proposed as an alternative immunosuppressive agent for treatment of severe aplastic anaemia, with a response rate similar to that with regimens containing antithymocyte globulin (ATG) but neither relapse nor clonal haematological complications. We undertook a phase III, prospective, randomised trial to compare response rates to immunosuppression with either high-dose cyclophosphamide plus ciclosporin or conventional immunosuppression with ATG plus ciclosporin in previously untreated patients. Methods: Between June, 1997, and March, 2000, 31 patients were enrolled. 15 were assigned cyclophosphamide (1 h intravenous infusion of 50 mg/kg daily for 4 days) and 16 were assigned ATG (40 mg/kg daily for 4 days); both groups received ciclosporin, initially at 12 mg/kg daily with adjustment to maintain concentrations at 200-400 μg/L, for 6 months. The primary endpoint was haematological response (no longer meeting criteria for severe aplastic anaemia). The trial was terminated prematurely after three early deaths in the cyclophosphamide group. Analyses were by intention to treat. Findings: Median follow-up was 21.9 months (range 1-33). There was excess morbidity in the cyclophosphamide group (invasive fungal infections, four cyclophosphamide vs no ATG patients; p=0.043) as well as excess early mortality (three deaths within the first 3 months cyclophosphamide vs no ATG patients; p=0.101). There was no significant difference at 6 months after treatment in the overall response rates among evaluable patients (six of 13 [46%] cyclophosphamide vs nine of 12 [75%] ATG). Interpretation: A longer period of observation will be necessary to assess the secondary endpoints of relapse and late clonal complications as well as disease-free and overall survival. However, cyclophosphamide seems a dangerous choice for treatment of this disorder, given the good results achievable with standard therapy.

AB - Background: High-dose cyclophosphamide has been proposed as an alternative immunosuppressive agent for treatment of severe aplastic anaemia, with a response rate similar to that with regimens containing antithymocyte globulin (ATG) but neither relapse nor clonal haematological complications. We undertook a phase III, prospective, randomised trial to compare response rates to immunosuppression with either high-dose cyclophosphamide plus ciclosporin or conventional immunosuppression with ATG plus ciclosporin in previously untreated patients. Methods: Between June, 1997, and March, 2000, 31 patients were enrolled. 15 were assigned cyclophosphamide (1 h intravenous infusion of 50 mg/kg daily for 4 days) and 16 were assigned ATG (40 mg/kg daily for 4 days); both groups received ciclosporin, initially at 12 mg/kg daily with adjustment to maintain concentrations at 200-400 μg/L, for 6 months. The primary endpoint was haematological response (no longer meeting criteria for severe aplastic anaemia). The trial was terminated prematurely after three early deaths in the cyclophosphamide group. Analyses were by intention to treat. Findings: Median follow-up was 21.9 months (range 1-33). There was excess morbidity in the cyclophosphamide group (invasive fungal infections, four cyclophosphamide vs no ATG patients; p=0.043) as well as excess early mortality (three deaths within the first 3 months cyclophosphamide vs no ATG patients; p=0.101). There was no significant difference at 6 months after treatment in the overall response rates among evaluable patients (six of 13 [46%] cyclophosphamide vs nine of 12 [75%] ATG). Interpretation: A longer period of observation will be necessary to assess the secondary endpoints of relapse and late clonal complications as well as disease-free and overall survival. However, cyclophosphamide seems a dangerous choice for treatment of this disorder, given the good results achievable with standard therapy.

UR - http://www.scopus.com/inward/record.url?scp=0034605715&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034605715&partnerID=8YFLogxK

M3 - Article

VL - 356

SP - 1554

EP - 1559

JO - The Lancet

JF - The Lancet

SN - 0140-6736

IS - 9241

ER -